{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:25:07Z","timestamp":1783401907669,"version":"3.54.6"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,6,24]],"date-time":"2015-06-24T00:00:00Z","timestamp":1435104000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1007\/s00280-015-2810-z","type":"journal-article","created":{"date-parts":[[2015,6,23]],"date-time":"2015-06-23T16:01:15Z","timestamp":1435075275000},"page":"409-416","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors"],"prefix":"10.1007","volume":"76","author":[{"given":"Toshihiko","family":"Doi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Yonemori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomu","family":"Fuse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Kodaira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Bando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Shimamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Ohtsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,6,24]]},"reference":[{"key":"2810_CR1","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2664","volume":"9","author":"JA Engelman","year":"2009","unstructured":"Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9:550\u2013562. doi: 10.1038\/nrc2664","journal-title":"Nat Rev Cancer"},{"key":"2810_CR2","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nchembio.183","volume":"5","author":"T Okuzumi","year":"2009","unstructured":"Okuzumi T, Fiedler D, Zhang C, Gray DC, Aizenstein B, Hoffman R, Shokat KM (2009) Inhibitor hijacking of Akt activation. Nat Chem Biol 5:484\u2013493. doi: 10.1038\/nchembio.183","journal-title":"Nat Chem Biol"},{"key":"2810_CR3","unstructured":"Yan L (2009) MK-2206: a potent oral allosteric AKT inhibitor [abstract #DDT01-1]. In: Proceedings of the 100th annual meeting of the American association for cancer research, Denver, CO, 18\u201322 Apr 2009"},{"key":"2810_CR4","unstructured":"Lu W, Defeo-Jones D, Davis L et al (2009) In vitro and in vivo antitumor activities of MK-2206, a new allosteric Akt inhibitor [abstract #3714]. In: Proceedings of the 100th annual meeting of the American association for cancer research, Denver, CO, 18\u201322 Apr 2009"},{"key":"2810_CR5","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1158\/1535-7163.MCT-09-1012","volume":"9","author":"H Hirai","year":"2010","unstructured":"Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS, Kotani H (2010) MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 9:1956\u20131967. doi: 10.1158\/1535-7163.MCT-09-1012","journal-title":"Mol Cancer Ther"},{"key":"2810_CR6","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1200\/JCO.2011.35.5263","volume":"29","author":"TA Yap","year":"2011","unstructured":"Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, Baird RD, Delgado L, Taylor A, Lupinacci L, Riisnaes R, Pope LL, Heaton SP, Thomas G, Garrett MD, Sullivan DM, de Bono JS, Tolcher AW (2011) First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 29:4688\u20134695. doi: 10.1200\/JCO.2011.35.5263","journal-title":"J Clin Oncol"},{"key":"2810_CR7","doi-asserted-by":"crossref","unstructured":"Biondo A, Yap TA, Yan L et al (2011) Phase I clinical trial of an allosteric AKT inhibitor, MK-2206, using a once weekly (QW) dose regimen in patients with advanced solid tumors. J Clin Oncol 29:(suppl; abstr 3037)","DOI":"10.1200\/jco.2011.29.15_suppl.3037"},{"issue":"20","key":"2810_CR8","doi-asserted-by":"crossref","first-page":"5672","DOI":"10.1158\/1078-0432.CCR-14-0868","volume":"15","author":"TA Yap","year":"2014","unstructured":"Yap TA, Yan L, Patnaik A, Tunariu N, Biondo A, Fearen I, Papadopoulos K, Olmos D, Baird RD, Delgado LM, Tetteh E, Beckman RA, Lupinacci L, Riisnaes R, Decordova S, Heaton SP, Swales K, deSouza NM, Leach MO, Garrett MD, Sullivan DM, de Bono JS, Tolcher A (2014) Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers. Clin Cancer Res 15(20):5672\u20135685. doi: 10.1158\/1078-0432","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2810_CR9","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/1740774507079442","volume":"4","author":"Y Ji","year":"2007","unstructured":"Ji Y, Li Y, Bekele BN (2007) Dose-finding in phase I clinical trials based on toxicity probability intervals. Clin Trials 4(3):235\u2013244","journal-title":"Clin Trials"},{"key":"2810_CR10","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/ijd.12205","volume":"53","author":"JL Curry","year":"2014","unstructured":"Curry JL, Torres-Cabala CA, Kim KB, Tetzlaff MT, Duvic M, Tsai KY, Hong DS, Prieto VG (2014) Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. Int J Dermatol 53:376\u2013384. doi: 10.1111\/ijd.12205","journal-title":"Int J Dermatol"},{"issue":"3","key":"2810_CR11","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.2011.36.1360","volume":"20;30","author":"JC Bendell","year":"2012","unstructured":"Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, Demanse D, De Buck SS, Ru QC, Peters M, Goldbrunner M, Baselga J (2012) Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 20;30(3):282\u2013290. doi: 10.1200\/JCO.2011.36.1360","journal-title":"J Clin Oncol"},{"key":"2810_CR12","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ccr.2007.08.030","volume":"12","author":"K Berns","year":"2007","unstructured":"Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12:395\u2013402","journal-title":"Cancer Cell"},{"key":"2810_CR13","doi-asserted-by":"crossref","first-page":"9221","DOI":"10.1158\/0008-5472.CAN-08-1740","volume":"68","author":"PJ Eichhorn","year":"2008","unstructured":"Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, Beijersbergen RL, Valero V, Seoane J, Bernards R, Baselga J (2008) Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR\/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 68:9221\u20139230. doi: 10.1158\/0008-5472.CAN-08-1740","journal-title":"Cancer Res"},{"key":"2810_CR14","first-page":"3986","volume":"61","author":"J Brognard","year":"2001","unstructured":"Brognard J, Clark AS, Ni Y, Dennis PA (2001) Akt\/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61:3986\u20133997","journal-title":"Cancer Res"},{"key":"2810_CR15","first-page":"1087","volume":"62","author":"L Hu","year":"2002","unstructured":"Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB (2002) Inhibition of phosphatidylinositol 3\u2032-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 62:1087\u20131092","journal-title":"Cancer Res"},{"key":"2810_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-8722-7-1","volume":"7","author":"LR Molife","year":"2014","unstructured":"Molife LR, Yan L, Vitfell-Rasmussen J, Zernhelt AM, Sullivan DM, Cassier PA, Chen E, Biondo A, Tetteh E, Siu LL, Patnaik A, Papadopoulos KP, de Bono JS, Tolcher AW, Minton S (2014) Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin\/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors. J Hematol Oncol 7:1. doi: 10.1186\/1756-8722-7-1","journal-title":"J Hematol Oncol"},{"key":"2810_CR17","doi-asserted-by":"crossref","first-page":"R110","DOI":"10.1186\/bcr3577","volume":"15","author":"C Hudis","year":"2013","unstructured":"Hudis C, Swanton C, Janjigian YY, Lee R, Sutherland S, Lehman R, Chandarlapaty S, Hamilton N, Gajria D, Knowles J, Shah J, Shannon K, Tetteh E, Sullivan DM, Moreno C, Yan L, Han HS (2013) A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors. Breast Cancer Res 15:R110. doi: 10.1186\/bcr3577","journal-title":"Breast Cancer Res"},{"key":"2810_CR18","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/2159-8274.CD-10-0010","volume":"1","author":"ES Kim","year":"2011","unstructured":"Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR Jr, Tsao A, Stewart DJ, Hicks ME, Erasmus J Jr, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK (2011) The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 1:44\u201353. doi: 10.1158\/2159-8274.CD-10-0010","journal-title":"Cancer Discov"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-015-2810-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2810-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2810-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T16:18:23Z","timestamp":1566922703000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-015-2810-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,24]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["2810"],"URL":"https:\/\/doi.org\/10.1007\/s00280-015-2810-z","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,24]]}}}